Boston Scientific Corporation (BSX) — Stock Price, Chart & Analysis
Boston Scientific Corporation (BSX) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $71.46B and a trailing P/E ratio of 19.96. Over the past 52 weeks, BSX has traded between $42.20 and $109.50. Boston Scientific Corporation does not currently pay a regular dividend. View the live BSX chart, technical opinion, analyst ratings, fundamentals and latest news below.
Boston Scientific Corporation (BSX) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $71.46B |
| P/E ratio (TTM) | 19.96 |
| EPS (TTM) | $2.47 |
| 52-week high | $109.50 |
| 52-week low | $42.20 |
| Beta | 0.57 |
| Avg. volume | 20.94M |
| Sector | Healthcare |
| Industry | Medical Devices |
Frequently asked questions about Boston Scientific Corporation (BSX)
How much does one share of Boston Scientific Corporation cost?
As of the latest update, one share of Boston Scientific Corporation (BSX) trades at $100 (+0.00% today).
What is Boston Scientific Corporation's market cap?
Boston Scientific Corporation has a market capitalization of approximately $71.46B.
What is Boston Scientific Corporation's P/E ratio?
Boston Scientific Corporation has a trailing price-to-earnings (P/E) ratio of 19.96.
What is Boston Scientific Corporation's earnings per share (EPS)?
Boston Scientific Corporation's trailing twelve-month EPS is $2.47.
Does Boston Scientific Corporation pay a dividend?
Boston Scientific Corporation does not currently pay a regular dividend.
What is Boston Scientific Corporation's 52-week trading range?
Over the past year, BSX has traded between $42.20 and $109.50.
What is the analyst price target for Boston Scientific Corporation?
The mean analyst price target for Boston Scientific Corporation is $62.69. This is informational only and not investment advice.
Latest Boston Scientific Corporation (BSX) news
- Boston Scientific (BSX) Q2 2026 Earnings Call TranscriptNews · Aug 8, 2026
- What Do Boston Scientific (BSX) Recalls Mean For Device Safety And Clinical Use?News · Aug 7, 2026
- Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?News · Aug 6, 2026
- ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in FocusNews · Aug 6, 2026
- ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?News · Aug 6, 2026
- Boston Scientific's 2026 Guidance Cut Puts Its Recovery to the TestNews · Aug 6, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live BSX dashboard…